Rólunk - Intelligenetic
IntelliGenetic Kft.
1138 Budapest, Népfürdő u. 22.
Duna Tower Office Building, Tower B, 15th Floor
Tel.: +36-1-700-1303
Fax: +36-1-700-1301
Email:
2003
Intelligenetic Healthcare Services Ltd. was founded by two obstetrician-gynecologist geneticists, pioneers of non-invasive prenatal testing in Hungary. Their first research results, published in 2003, were followed by numerous articles in prestigious domestic and international journals, regular presentations at Hungarian and international professional conferences, the award of their Ph.D. degrees in 2007 on the topic, and later contributions to textbook chapters and university lectures for current and future doctors.
One of the experts who later joined Intelligenetic — now a university professor — had a long-standing professional relationship and friendship with the founders: as early as 2006, they published a study in a journal ranked in the top 10% of their field that was based on whole-genome analysis, considered a curiosity even on an international level.
2013
Intelligenetic Ltd. was established in 2013 with the aim of making the Verifi® test available to expectant mothers in Hungary. The Verifi® non-invasive prenatal test (NIPT) was developed by Verinata Health, a subsidiary of Illumina, one of the world’s largest genetic research companies.
The Hungarian company entered into a partnership agreement with the American biotechnology firm, as the founders were already known internationally by that time. Illumina is a leading developer, manufacturer, and distributor of life sciences tools and integrated systems for large-scale analysis of genetic variation and function. These systems enable studies that were unimaginable just a few years ago and bring us closer to realizing personalized medicine.
While thousands of expectant mothers underwent NIPT, Intelligenetic’s researchers also conducted numerous other studies in clinical and molecular genetics, oncogenetics, and bioinformatics.
2022
In 2022, the NIPT offered by Intelligenetic was renewed: the Verifi® test was replaced by IntelliNIPT™.
The new IntelliNIPT™ test continues to be based on technology from Illumina, the provider behind the Verifi® test.
From early 2022, Intelligenetic’s partner has been Veritas Intercontinental, “The Genome Company,” a multinational leader in DNA sequencing and interpretation. The clinical team at Veritas Intercontinental is made up of internationally recognized experts with more than 20 years of experience in prenatal diagnostics and genetic counseling. They are pioneers in the development of non-invasive prenatal tests and their integration into routine clinical practice in Europe.
In addition to long-standing professional relationships with their leading colleagues, shared traditions support the cooperation.
Intelligenetic’s goal is to make the most advanced testing options available to Hungarian doctors and their patients by involving world-renowned researchers and highly trained scientists, and by continuously monitoring and organizing the latest technologies and medical innovations.
Verifi® is a trademark of Illumina, Inc.
IntelliNIPT™ is a trademark of Intelligenetic. All other trademarks are the property of their respective owners.
IntelliGenetic Kft.
Duna Tower Irodaház B torony 15. emelet
Tel.: +36-1-700-1303
Fax: + 36-1-700-1301
Email:
2003
Intelligenetic Healthcare Services Ltd. was founded by two obstetrician-gynecologist geneticists, pioneers of non-invasive prenatal testing in Hungary. Their first research results, published in 2003, were followed by numerous articles in prestigious domestic and international journals, regular presentations at Hungarian and international professional conferences, the award of their Ph.D. degrees in 2007 on the topic, and later contributions to textbook chapters and university lectures for current and future doctors.
One of the experts who later joined Intelligenetic — now a university professor — had a long-standing professional relationship and friendship with the founders: as early as 2006, they published a study in a journal ranked in the top 10% of their field that was based on whole-genome analysis, considered a curiosity even on an international level.
2013
Intelligenetic Ltd. was established in 2013 with the aim of making the Verifi® test available to expectant mothers in Hungary. The Verifi® non-invasive prenatal test (NIPT) was developed by Verinata Health, a subsidiary of Illumina, one of the world’s largest genetic research companies.
The Hungarian company entered into a partnership agreement with the American biotechnology firm, as the founders were already known internationally by that time. Illumina is a leading developer, manufacturer, and distributor of life sciences tools and integrated systems for large-scale analysis of genetic variation and function. These systems enable studies that were unimaginable just a few years ago and bring us closer to realizing personalized medicine.
While thousands of expectant mothers underwent NIPT, Intelligenetic’s researchers also conducted numerous other studies in clinical and molecular genetics, oncogenetics, and bioinformatics.
2022
In 2022, the NIPT offered by Intelligenetic was renewed: the Verifi® test was replaced by IntelliNIPT™.
The new IntelliNIPT™ test continues to be based on technology from Illumina, the provider behind the Verifi® test.
From early 2022, Intelligenetic’s partner has been Veritas Intercontinental, “The Genome Company,” a multinational leader in DNA sequencing and interpretation. The clinical team at Veritas Intercontinental is made up of internationally recognized experts with more than 20 years of experience in prenatal diagnostics and genetic counseling. They are pioneers in the development of non-invasive prenatal tests and their integration into routine clinical practice in Europe.
In addition to long-standing professional relationships with their leading colleagues, shared traditions support the cooperation.
Intelligenetic’s goal is to make the most advanced testing options available to Hungarian doctors and their patients by involving world-renowned researchers and highly trained scientists, and by continuously monitoring and organizing the latest technologies and medical innovations.
Verifi® is a trademark of Illumina, Inc.
IntelliNIPT™ is a trademark of Intelligenetic. All other trademarks are the property of their respective owners.
Dr. Gyula Richárd Nagy graduated summa cum laude from Semmelweis University. He is currently an Associate Professor (habilitated) at the Department of Obstetrics and Gynecology, Semmelweis University, as well as an obstetrician-gynecologist, clinical geneticist, and healthcare manager. He is the lead instructor in the English-language medical program of the Clinic.
In numerous scientific works, he has focused on non-invasive prenatal testing, being considered a pioneer of the field in Hungary. He has reported findings suggesting that in pregnancies at advanced maternal age, long-term oral contraception before conception may reduce the risk of Down syndrome.
He has participated in organizing many domestic and international medical congresses, and has chaired numerous medical conferences and professional training courses. He is a member of several medical societies and the founding president of the Young Gynecologists’ Society.
Prof. Dr. Balázs Győrffy studied medicine at Semmelweis University in Budapest and at Ruprecht-Karls University in Heidelberg. He has published more than 300 scientific papers, filed several patents, and earned his doctoral degree in molecular genetics and bioinformatics.
He has worked for several years at Charité Universitätsmedizin Berlin (Germany) and Harvard University (Boston, USA). He is a specialist in bioinformatic evaluation of genomic data. According to the Web of Science, he is one of the four “highly cited” researchers working in Hungary.
Zoltán Urbán is a paramedic, healthcare manager, and political marketing and communications consultant. He obtained his bachelor’s and master’s degrees at Semmelweis University, and after postgraduate training, earned a degree from Corvinus University.
He is a lecturer at the Department of Oxyology and Emergency Care, Semmelweis University. He is a member of the Hungarian Society of Cardiology and the Hungarian Society of Emergency Medicine.
From 1998 to 2019, he served as an on-site paramedic with the National Ambulance Service. During this period, he contributed as author or co-author to the development of several protocols related to emergency care.
He currently leads several research and development projects related to preventive medicine and acts as a health policy advisor on personalized medicine.
Dr. András György is an attorney specializing in legal consulting on intellectual property. He is a member of the Industrial Property Expert Board (ISZT) and the Copyright Expert Board (SzJSzT), both operating alongside the Hungarian Intellectual Property Office.
In addition to intellectual property, his other area of expertise is data protection. He serves as Data Protection Officer (DPO) for several research and development institutions.
Prof. Dr. Bálint Nagy is a university professor and former head of the Department of Human Genetics at the University of Debrecen. He is currently Editor-in-Chief of Elsevier Molecular and Cellular Probes.
He graduated in Biology from the Faculty of Science, József Attila University, in 1980, and earned the title “Doctor of Pharmaceutical Sciences” at Semmelweis University of Medicine in 1986.
He obtained his PhD in Fetal and Neonatal Medicine at Semmelweis University in 2010, habilitated in Clinical Genetics in 2011, and earned the title “Doctor of the Hungarian Academy of Sciences” in 2015.
His research interests include non-invasive diagnostics and the molecular genetic background of various complex diseases. He has introduced several diagnostic methods into fetal diagnostics and has worked on the detection of free nucleic acids from non-invasively collected samples since 2004.
His scientific output includes 123 publications in English, 71 in Hungarian, nearly 6,000 citations, and a Hirsch index of 43.
Prof. Dr. Thomas Karn is currently a Professor at the Department of Obstetrics and Gynecology, Goethe University Frankfurt am Main, and Director of Translational Research.
He conducts research in molecular biology and oncology, has an H-index of 47, and has been cited over 9,000 times.
Partners
